Influence of BRAF mutations and RAC1b/RAC1 mRNA ratio or protein expression on outcome in patients with metastatic Colorectal Cancer (mCRC) treated with first-line chemotherapy

被引：0
|
作者：
Cuatrecasas, M. [1 ]
Alonso-Espinaco, V. [1 ]
Jares, P. [1 ]
Horndler, C. [1 ]
Castells, A. [1 ]
Lozano, J. J. [1 ]
Maurel, J. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
来源：
VIRCHOWS ARCHIV | 2012年 / 461卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
    Nakayama, Izuma
    Shinozaki, Eiji
    Matsushima, Tomohiro
    Wakatsuki, Takeru
    Ogura, Mariko
    Ichimura, Takashi
    Ozaka, Masato
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Mizunuma, Nobuyuki
    Yamaguchi, Kensei
    BMC CANCER, 2017, 17
  • [32] Prognostic and predictive significance of CD15 and neutrophil/lymphocyte ratio (NTR) in metastatic colorectal cancer (mCRC) patients (pts) undergoing to first-line chemotherapy (CT).
    Giordano, Guido
    Febbraro, Antonio
    Tomaselli, Eugenio
    Parente, Domenico
    Forte, Nicola
    Scrocco, Dario
    Venditti, Michele
    Sarnicola, Maria Lucia
    Parcesepe, Pietro
    Manfrin, Erminia
    Remo, Andrea
    Pancione, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy
    Suzuki, C.
    Blomqvist, L.
    Sundin, A.
    Bystrom, P.
    Berglund, A.
    Jacobsson, H.
    Nygren, P.
    Glimelius, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] MODIFIED FLOX (MFLOX) WITH LOW-DOSE LEUCOVORIN AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED WITHIN THE PUBLIC HEALTH SYSTEM IN BRAZIL
    Nebuloni, D. R.
    Mak, M. P.
    Saragiotto, D. F.
    Julio, T.
    Viana, P. C. C.
    Castro Jr, G.
    Sabbaga, J.
    Hoff, P. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 119 - 119
  • [35] Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC)
    Tahara, M.
    Yamada, Y.
    Ohtsu, A.
    Shirao, K.
    Shimada, Y.
    Sasaki, Y.
    Yamamoto, W.
    Satoh, T.
    Okamoto, W.
    Tanigawara, Y.
    EJC SUPPLEMENTS, 2007, 5 (04): : 254 - 254
  • [36] Tumor genetic analysis of PRIME: KRAS, NRAS, and BRAF mutations as predictive biomarkers in patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with panitumumab (pmab)+FOLFOX4
    Oliner, K.
    Douillard, J. Y.
    Siena, S.
    Tabernero, J.
    Burkes, R.
    Barugel, M.
    Humblet, Y.
    Rong, A.
    Sidhu, R.
    Patterson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S520 - S521
  • [37] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
    Thibaudin, Marion
    Fumet, Jean-David
    Chibaudel, Benoist
    Bennouna, Jaafar
    Borg, Christophe
    Martin-Babau, Jerome
    Cohen, Romain
    Fonck, Marianne
    Taieb, Julien
    Limagne, Emeric
    Blanc, Julie
    Ballot, Elise
    Hampe, Lea
    Bon, Marjorie
    Daumoine, Susy
    Peroz, Morgane
    Mananet, Hugo
    Derangere, Valentin
    Boidot, Romain
    Michaud, Henri-Alexandre
    Laheurte, Caroline
    Adotevi, Olivier
    Bertaut, Aurelie
    Truntzer, Caroline
    Ghiringhelli, Francois
    NATURE MEDICINE, 2023, 29 (08) : 2087 - +
  • [38] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
    Marion Thibaudin
    Jean-David Fumet
    Benoist Chibaudel
    Jaafar Bennouna
    Christophe Borg
    Jerome Martin-Babau
    Romain Cohen
    Marianne Fonck
    Julien Taieb
    Emeric Limagne
    Julie Blanc
    Elise Ballot
    Léa Hampe
    Marjorie Bon
    Susy Daumoine
    Morgane Peroz
    Hugo Mananet
    Valentin Derangère
    Romain Boidot
    Henri-Alexandre Michaud
    Caroline Laheurte
    Olivier Adotevi
    Aurélie Bertaut
    Caroline Truntzer
    François Ghiringhelli
    Nature Medicine, 2023, 29 : 2087 - 2098
  • [39] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial
    Thibaudin, Marion
    Fumet, Jean-David
    Limagne, Emeric
    Hampe, Lea
    Daumoine, Susy
    Derangere, Valentin
    Laheurte, Caroline
    Adotevi, Olivier
    Truntzer, Caroline
    Ghiringhelli, Francois
    CANCER RESEARCH, 2024, 84 (07)
  • [40] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
12345